|
As President of Metagenics, Jean Bellin is responsible for worldwide sales, marketing, manufacturing operations, quality control, and human resources. He has more than 25 years experience in the pharmaceutical industry, including sales, marketing, business development, mergers and acquisitions, and general management—both domestic and international.
Mr. Bellin began his pharmaceutical industry career with 12 years at Eli Lilly & Company, holding positions in sales, marketing, and general management in Brazil, the U.S., the Scandinavian countries, and Italy. He then founded and served as Managing Director of DuPont Pharma Italy.
In 1993, Mr. Bellin became the head of the international division of UCB, a $2 billion publicly-traded, biopharmaceutical group based in Brussels, Belgium. There he managed the pharmaceutical subsidiaries in the U.S., Canada, South America, Japan, China, and Southeast Asia. Later he managed the osteohealth and animal health divisions of Sankyo Pharmaceuticals Company, Ltd., then the second largest pharmaceutical company in Japan. More recently, he was the Chief Executive Officer of Mountain View Pharmaceuticals, Inc., a California-based biopharmaceutical company, where the PEGylation of therapeutic proteins was a major focus.
Mr. Bellin received his bachelor’s degree in Economic, Political, and Social Sciences from Facultés Universitaires Saint Louis in Brussels and a license in applied economic sciences from the Université Catholique de Louvain in Belgium. Mr. Bellin also currently serves on the board of directors for KV Pharmaceutical Company, a publicly-traded, specialty pharmaceutical company based in St. Louis, Missouri. He is fluent in four languages, including English, French, Italian, and Portuguese. | 